BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32344303)

  • 1. Oxytocin as a potential defence against Covid-19?
    Soumier A; Sirigu A
    Med Hypotheses; 2020 Jul; 140():109785. PubMed ID: 32344303
    [No Abstract]   [Full Text] [Related]  

  • 2. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
    Severa M; Farina C; Salvetti M; Coccia EM
    Front Immunol; 2020; 11():1459. PubMed ID: 32655578
    [No Abstract]   [Full Text] [Related]  

  • 3. Purposing Saikosaponins for the treatment of COVID-19.
    Bahbah EI; Negida A; Nabet MS
    Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.
    Sarma P; Prajapat M; Avti P; Kaur H; Kumar S; Medhi B
    Indian J Pharmacol; 2020; 52(1):1-5. PubMed ID: 32201439
    [No Abstract]   [Full Text] [Related]  

  • 5. Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology.
    Dal Moro F; Livi U
    Clin Immunol; 2020 May; 214():108414. PubMed ID: 32272196
    [No Abstract]   [Full Text] [Related]  

  • 6. Curing COVID-19.
    The Lancet Infectious Diseases
    Lancet Infect Dis; 2020 Oct; 20(10):1101. PubMed ID: 32919520
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatments for COVID-19: where are we now?
    Mendes A
    Br J Community Nurs; 2020 Aug; 25(8):412-413. PubMed ID: 32757900
    [No Abstract]   [Full Text] [Related]  

  • 8. Current Perspective of Antiviral Strategies against COVID-19.
    Ahidjo BA; Loe MWC; Ng YL; Mok CK; Chu JJH
    ACS Infect Dis; 2020 Jul; 6(7):1624-1634. PubMed ID: 32485102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plea for multitargeted interventions for severe COVID-19.
    Gaborit BJ; Bergmann JF; Mussini C; Arribas JR; Behrens G; Walmsley S; Pozniak A; Raffi F
    Lancet Infect Dis; 2020 Oct; 20(10):1122-1123. PubMed ID: 32325035
    [No Abstract]   [Full Text] [Related]  

  • 10. Investigating hypothiocyanite against SARS-CoV-2.
    Cegolon L
    Int J Hyg Environ Health; 2020 Jun; 227():113520. PubMed ID: 32305009
    [No Abstract]   [Full Text] [Related]  

  • 11. Is Coronavirus Disease 2019 (COVID-19) seen less in countries more exposed to Malaria?
    Sargin G; Yavaşoğlu Sİ; Yavasoglu I
    Med Hypotheses; 2020 Jul; 140():109756. PubMed ID: 32344306
    [No Abstract]   [Full Text] [Related]  

  • 12. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
    Nisole S; Saulnier A; Gatignol A
    Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
    [No Abstract]   [Full Text] [Related]  

  • 13. Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
    Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR
    Int J Antimicrob Agents; 2020 Apr; 55(4):105933. PubMed ID: 32147516
    [No Abstract]   [Full Text] [Related]  

  • 14. Famotidine Against SARS-CoV2: A Hope or Hype?
    Ghosh R; Chatterjee S; Dubey S; Lavie CJ
    Mayo Clin Proc; 2020 Aug; 95(8):1797-1799. PubMed ID: 32753153
    [No Abstract]   [Full Text] [Related]  

  • 15. Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.
    Poulas K; Farsalinos K; Zanidis C
    Front Immunol; 2020; 11():1373. PubMed ID: 32612613
    [No Abstract]   [Full Text] [Related]  

  • 16. Sofosbuvir as a potential option for the treatment of COVID-19.
    Nourian A; Khalili H
    Acta Biomed; 2020 May; 91(2):236-238. PubMed ID: 32420958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Potential Therapeutic Options for COVID-19.
    Austin D; Okour M
    J Clin Pharmacol; 2020 Aug; 60(8):976-977. PubMed ID: 32469418
    [No Abstract]   [Full Text] [Related]  

  • 18. Sofosbuvir for COVID-19 infection: A potential candidate.
    Gupta R; Dhamija P
    Indian J Pharmacol; 2020; 52(3):232-233. PubMed ID: 32874010
    [No Abstract]   [Full Text] [Related]  

  • 19. Favipiravir, an antiviral for COVID-19?
    Coomes EA; Haghbayan H
    J Antimicrob Chemother; 2020 Jul; 75(7):2013-2014. PubMed ID: 32417899
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug researchers pursue new lines of attack against COVID-19.
    Harrison C
    Nat Biotechnol; 2020 Jun; 38(6):659-662. PubMed ID: 32417850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.